Radium-223 Extends Survival in CRPC

Home » Radium-223 Extends Survival in CRPC

Men with metastatic castration-resistant prostate cancer (CRPC) lived significantly longer when treated with a bone-targeted, alpha-emitting agent, a randomized trial showed.

Leave a Comment

Scroll to Top